Cure8 research brief
Detecting molecular signs of IBD before symptoms could eventually allow earlier monitoring or preventive strategies, changing how and when people at risk are identified. For patients, this research points to hope that future biomarker panels might enable interventions earlier in the disease course.
Researchers studying IBD biomarkers, clinicians interested in early detection or preventive strategies, and patients or advocates following advances in IBD screening and pathogenesis research.
This review highlights evidence that inflammatory bowel disease (IBD) often has a prolonged preclinical phase during which molecular signals — including antimicrobial/antiviral antibodies, circulating immune proteins, chemokine signatures, and markers of early tissue injury — can be detected years before symptoms.
The authors describe how integrated panels of these molecular features could become scalable biomarker approaches to detect preclinical IBD and possibly identify proximal drivers (dysregulated mononuclear phagocyte–lymphocyte interactions, interferon-γ–related chemotaxis, and perturbed host–microbe interactions).
This article is an abstracted review (Gut) summarizing current cohort-based molecular profiling findings rather than reporting a single new trial or diagnostic test.
If you’re interested in implications for early detection, screening, or future prevention strategies, the review provides a research-focused overview but does not present a validated clinical test.
This is a review/summary of cohort-based molecular profiling studies (abstract-level content). The findings describe associations and potential biomarkers rather than validated clinical diagnostics. Further research and validation are needed before any change to clinical practice.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Competing interests: NP has been a speaker, advisory consultant or has received research grants from: Abbvie, Alimentiv, Allergan, Astra-Zeneca, Bristol-Myers Squibb, Celgene, Celltrion, Dr Falk Pharma UK Ltd, Ferring, Galapagos, GSK, Janssen, MSD, Roche, Pfizer, Sobi, Takeda, Tillotts and Vifor.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
miRNAs are being studied as stable circulating biomarkers and possible therapeutic targets in immune diseases including IBD. Advances could eventually improve earlier diagnosis, track disease course, or lead to new...
This narrative review surveys novel biomarkers and therapeutic strategies for adult IBD, topics that could affect diagnosis, monitoring, and future treatment options for people with Crohn's disease or ulcerative colitis.
Researchers are investigating circRNAs as potential biomarkers and therapeutic targets in IBD because they may help explain disease mechanisms and lead to better diagnostics or treatments in the future.
